Skip to main content
. 2020 Apr 22;11:311. doi: 10.3389/fgene.2020.00311

FIGURE 1.

FIGURE 1

(A) Differences in mRNAsi between normal (57 samples) and LUAD (385 samples) tissues. (B) Differences in mRNAsi between LUAD patients without recurrence (154 samples) and with recurrence (46 samples) after primary treatment without adjuvant therapy. (C) Differences in mRNAsi between LUAD patients with M0 (370 samples) and M1 (15 samples) stage. (D) Comparison of mRNAsi in four different T stages (T1, 124 samples; T2, 75 samples; T3, 32 samples; T4, 9 samples). (E) Comparison of mRNAsi in four different N stages (N0, 260 samples; N1, 75 samples; N2, 48 samples; N3, 2 samples). (F) Comparison of mRNAsi in four different AJCC stages (Stage I, 215 samples; Stage II, 99 samples; Stage III, 56 samples; Stage IV, 15 samples). (G) Kaplan–Meier curves show that the low mRNAsi group had a better prognosis than the high mRNAsi group for OS. (H) Volcano map of differentially expressed genes; green indicates downregulated genes, and red indicates upregulated genes. (I) Kaplan–Meier curves show that the low mRNAsi group had a better prognosis than the high mRNAsi group for PFS. LUAD, lung adenocarcinoma; mRNAsi, mRNA expression-based stemness index; AJCC, American Joint Committee on Cancer; OS, overall survival; PFS, progression-free survival.